Related Experiment Video
Updated: Dec 19, 2025
04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
1.0K
A Sympathetic Treatment for Obesity
1Program in Cell Signaling and Neurobiology of Metabolism, Yale University School of Medicine, New Haven, CT 06520, USA; Departments of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Cell Metabolism
|June 4, 2020
Summary
A new amphetamine derivative, PEGylated amphetamine (PEGyAMPH), shows potential as an anti-obesity drug. This brain-spared compound alters sympathetic activity without the cardiovascular risks associated with traditional amphetamines.
Area of Science:
- Pharmacology
- Neuroscience
- Obesity Research
Background:
- Amphetamine (AMPH) exhibits weight loss properties but carries significant cardiovascular risks.
- Existing treatments for attention deficit hyperactivity disorder and narcolepsy often have limitations.
Purpose of the Study:
- To investigate the anti-obesity effects of a novel amphetamine derivative, PEGylated amphetamine (PEGyAMPH).
- To assess whether PEGylated amphetamine (PEGyAMPH) can mitigate the cardiovascular side effects associated with amphetamine-based treatments.
Main Methods:
- Development of a brain-spared PEGylated amphetamine (PEGyAMPH) derivative.
- Evaluation of sympathetic activity modulation by PEGylated amphetamine (PEGyAMPH).
- Assessment of cardiovascular safety profile of PEGylated amphetamine (PEGyAMPH).
Main Results:
- PEGylated amphetamine (PEGyAMPH) demonstrates efficacy as an anti-obesity agent.
- The novel derivative modulates sympathetic activity effectively.
- Crucially, PEGylated amphetamine (PEGyAMPH) avoids the detrimental cardiovascular effects seen with traditional amphetamine (AMPH).
Conclusions:
- PEGylated amphetamine (PEGyAMPH) represents a promising therapeutic candidate for obesity management.
- This brain-spared approach offers a safer alternative to conventional amphetamine-based weight loss strategies.
- Further research into PEGylated amphetamine (PEGyAMPH) could lead to improved obesity treatments with enhanced cardiovascular safety.
More Related Videos
Related Concept Videos
01:16Sympathetic Activation
6.4K
The sympathetic division can influence tissues and organs by releasing norepinephrine at peripheral synapses and distributing epinephrine and norepinephrine through the bloodstream. In times of crisis or stress, sympathetic activation occurs, which is regulated by sympathetic centers in the hypothalamus. As a result, sympathetic activation prepares the body for physical exertion, rapid ATP production, and heightened alertness, allowing individuals to respond effectively to challenging or...
6.4K
01:24Obesity
1.0K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.0K
01:30Adrenergic Agonists: Therapeutic Uses
1.5K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.5K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
162
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
162
01:25The Sympathetic Nervous System
102.2K
Overview
102.2K
01:18Adrenergic Agonists: Therapeutic Classification
1.3K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.3K